<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The purpose of these studies was to develop immunogenic <z:chebi fb="7" ids="16670">peptides</z:chebi> derived from the CD19 and CD20 self-antigens for the induction of antigen-specific CTLs against B-cell <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>A total of seven <z:chebi fb="7" ids="16670">peptides</z:chebi> were designed and examined for their HLA-A2.1 affinity and immunogenicity </plain></SENT>
<SENT sid="2" pm="."><plain>Of these <z:chebi fb="7" ids="16670">peptides</z:chebi>, we identified two highly immunogenic HLA-A2.1-specific <z:chebi fb="7" ids="16670">peptides</z:chebi>, CD19(150-158) (KLMSPKLYV) and CD20(188-196) (SLFLGILSV), which were capable of inducing <z:chebi fb="7" ids="16670">peptide</z:chebi>-specific CTLs </plain></SENT>
<SENT sid="3" pm="."><plain>The CTLs displayed HLA-A2.1-restricted and antigen-specific cytotoxicity against Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, <z:hpo ids='HP_0011010'>chronic</z:hpo> B cell <z:hpo ids='HP_0001909'>leukemia</z:hpo>, and <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo> cell lines </plain></SENT>
<SENT sid="4" pm="."><plain>The CD19 or CD20 <z:chebi fb="7" ids="16670">peptide</z:chebi>-specific CTL cytotoxicity was confirmed using HLA-A2.1(+) T2 cells presenting the appropriate <z:chebi fb="7" ids="16670">peptide</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain>No cytotoxic activity was observed against T2 cells presenting the irrelevant MAGE-3 peptide or T2 cells alone </plain></SENT>
<SENT sid="6" pm="."><plain>In addition, the CTLs displayed a significant (P &lt; 0.05) increase in cell proliferation and IFN-gamma secretion (&gt;830 ng/mL) following restimulation with HLA-A2.1(+)/CD19(+)/CD20(+) <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells </plain></SENT>
<SENT sid="7" pm="."><plain>The CTLs also displayed a distinct phenotype consisting of a high percentage of CD69(+)/CD45RO(+) and a low percentage of CD45RA(+)/CCR7(+) CD4(+) or CD8(+) T cells characteristic of effector memory cell population </plain></SENT>
<SENT sid="8" pm="."><plain>Cyclic <z:chebi fb="0" ids="16750">guanosine</z:chebi> 3',5'-monophosphate culture conditions using serum-free AIM-V medium containing human AB serum, recombinant human interleukin 2 (Proleukin) and CD3/CD28 Dynabeads were developed resulting in a 35-fold expansion of CD20 <z:chebi fb="7" ids="16670">peptide</z:chebi>-specific CTLs </plain></SENT>
<SENT sid="9" pm="."><plain>The expanded CD20-CTLs retained their cytotoxic activity (28-49%) against the Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cell line </plain></SENT>
<SENT sid="10" pm="."><plain>In conclusion, we report here on the identification of novel immunogenic CD19(150-158) (KLMSPKLYV) and CD20(188-196) (SLFLGILSV) <z:chebi fb="7" ids="16670">peptides</z:chebi> that have immunotherapeutic potentials as <z:chebi fb="7" ids="16670">peptide</z:chebi> vaccines or targeted T-cell therapies for treating B-cell <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
</text></document>